Familial Nasopharyngeal Carcinoma 6

274 Y. Guo and B. S. GlissonHasbini A, Mahjoubi R, Fandi A, et al (1999) Phase II trialcombining mitomycin with 5-fluorouracil, epirubicin, andcisplatin in recurrent and metastatic undifferentiated carcinomaof nasopharyngeal type. Ann Oncol 10(4):421–425Jiang Y, Wei WI, Luo F, et al (2005) Gemcitabine and cisplatin inadvanced nasopharyngeal carcinoma: a pilot study. CancerInvest 23(2):123–128Johnson FM, Garden A, Palmer JL, et al (2004) A phase II studyof docetaxel and carboplatin as neoadjuvant therapy fornasopharyngeal carcinoma with early T status andadvanced N status.Cancer 100:991–998Kam MK, Teo PM, Chau RM, et al (2004) Treatment of nasopharyngealcarcinoma with intensity-modulated radiotherapy:the Hong Kong experience. Int J Radiat Oncol Biol Phys60(5):1440–1450Lee AW, Foo W, Mang O, et al (2003) Changing epidemiology ofnasopharyngeal carcinoma in Hong Kong over a 20-yearperiod (1980–99): an encouraging reduction in both incidenceand mortality. Int J Cancer 103(5):680–685Leong JL, Lok KS, Putti TC, et al (2004) Epidermal growth factorreceptor in undifferentiated carcinoma of the nasopharynx.Laryngoscope 114(1):153–157Leong SS, Wee J, Tay MH, et al (2005) Paclitaxel, carboplatin,and gemcitabine in metastatic nasopharyngeal carcinoma:a phase II trial using a triplet combination. Cancer 103(3):569–575Li YH, Wang FH, Jiang WQ, et al (2008) Phase II study of capecitabineand cisplatin combination as first-line chemotherapyin Chinese patients with metastatic nasopharyngeal carcinoma.Cancer Chemother Pharmacol 62(3):539–544Lin CL, Lo WF, Lee TH, et al (2002) Immunization withEpstein–Barr Virus peptide-pulsed dendritic cells inducesfunctional CD8 + T-cell immunity and may lead to tumorregression in patients with EBV-positive nasopharyngealcarcinoma. Cancer Res 62(23):6952–6958Lin JC, Jan JS, Hsu CY, et al (2003) Phase III study of concurrentchemoradiotherapy versus radiotherapy alone foradvanced nasopharyngeal carcinoma: positive effect onoverall and progression-free survival. J Clin Oncol 21(4):631–637Lin JC, Wang WY, Chen KY, et al (2004) Quantification of plasmaEpstein–Barr virus DNA in patients with advanced nasopharyngealcarcinoma. N Engl J Med 350(24):2461–2470Ma BB, Tannock IF, Pond GR, et al (2002) Chemotherapy withgemcitabine-containing regimens for locally recurrent or metastaticnasopharyngeal carcinoma. Cancer 95(12):2516–2523McCarthy J, Tannock I, Degendorfer P, et al (2002) A Phase IItrial of docetaxel and cisplatin in patients with recurrentor metastatic nasopharyngeal carcinoma. Oral Oncol38(7):686Ngan RK, Yiu HH, Lau WH, et al (2002) Combination gemcitabineand cisplatin chemotherapy for metastatic orrecurrent nasopharyngeal carcinoma: report of a phase IIstudy. Ann Oncol 13(8):1252–1258Poon D, Chowbay B, Cheung YB, et al (2005) Phase II study ofirinotecan (CPT-11) as salvage therapy for advancednasopharyngeal carcinoma. Cancer 10(3):576–581Siu LL, Czaykowski PM, Tannock IF (1998) Phase I/II study of theCAPABLE regimen for patients with poorly differentiatedcarcinoma of the nasopharynx. J Clin Oncol 16(7):2514–2521Straathof KC, Bollard CM, Popat U, et al (2005) Treatment ofnasopharyngeal carcinoma with Epstein–Barr virus-specificT lymphocytes. Blood 105:1898–1904Sung FL, Poon TC, Hui EP, et al (2005) Antitumor effect andenhancement of cytotoxic drug activity by cetuximab innasopharyngeal carcinoma cells. In Vivo 19:237–245Su WC, Chen TY, Kao RH, et al (1993) Chemotherapy with cisplatinand continuous infusion of 5-fluorouracil and bleomycinfor recurrent and metastatic nasopharyngeal carcinoma inTaiwan. Oncology 50(4):205–208Taamma A, Fandi A, Azli N, Wibault P, et al (1999) Phase II trialof chemotherapy with 5-fluorouracil, bleomycin, epirubicin,and cisplatin for patients with locally advanced, metastatic,or recurrent undifferentiated carcinoma of thenasopharyngeal type. Cancer 86(7):1101–1108Tan EH, Khoo KS, Wee J, et al (1999) Phase II trial of a paclitaxeland carboplatin combination in Asian patients with metastaticnasopharyngeal carcinoma. Ann Oncol 10(2):235–237Teo PM, Kwan WH, Lee WY, et al (1996) Prognosticators determiningsurvival subsequent to distant metastasis fromnasopharyngeal carcinoma. Cancer 77:2423–2431Toh CK, Heng D, Ong YK, et al (2005) Validation of a new prognosticindex score for disseminated nasopharyngeal carcinoma.Br J Cancer 92(8):1382–1387Wang CC, Liu TW, Lin CY, et al (2006) Phase II study of gemcitabineplus vinorelbine in the treatment of cisplatin-resistantnasopharyngeal carcinoma. Head Neck 28(1):74–80Wee J, Tan EH, Tai BC, et al (2005) Randomized trial of radiotherapyversus concurrent chemoradiotherapy followed byadjuvant chemotherapy in patients with American JointCommittee on Cancer/International Union against cancerstage III and IV nasopharyngeal cancer of the endemicvariety. J Clin Oncol 23(27):6730–6738Yeo W, Leung TW, Chan AT, et al (1998) A Phase II study ofcombination paclitaxel and carboplatin in advancednasopharyngeal carcinoma. Eur J Cancer 34:2027–2031Yeo W, Leung TW, Leung SF, et al (1996) Phase II study of thecombination of carboplatin and 5-fluorouracil in metastaticnasopharyngeal carcinoma. Cancer Chemother Pharmacol38(5):466–470Zhang L, Zhang Y, Huang PY, et al (2008) Phase II clinical study ofgemcitabine in the treatment of patients with advancednasopharyngeal carcinoma after the failure of platinum-basedchemotherapy. Cancer Chemother Pharmacol 61:33–38